M&A Hunter

Bio stock M&A player
Best selling Sub Stack top 100 Finance & bestseller top 5 Biotech & the ONLY M&A Stack

[M&A Hunter @TheBioMAHunter]

June 25, 2026 | 52-Week Highs and Lows
52-Week Highs

ALKS | Alkermes | $51.73. Alkermes is getting marked up because the market is treating it as a commercial biotech with real earnings durability rather than a late-stage pipeline lottery ticket.

MGTX | MeiraGTx | $12.28. MeiraGTx is drawing a higher bid as investors keep leaning into gene therapy programs that still have enough clinical depth to matter.
PGEN | Precigen | $5.61. Precigen’s move reflects continued willingness to fund a differentiated CAR-T and immunotherapy story even though the company is still proving its commercial path.
XBI | SPDR S&P Biotech ETF | $148.76. XBI hitting a fresh high tells you biotech risk appetite is still broadening across the sector, not just concentrating in one or two momentum names.

ELVN | Enliven Therapeutics | $49.94. Enliven is being re-rated as an oncology name with a cleaner development profile that still has meaningful upside if the pipeline keeps advancing.
DNLI | Denali Therapeutics | $25.69. Denali is getting more support as the market continues to value its neurodegeneration platform as a credible long-duration science story.
DFTX | Dogwood Therapeutics | $44.54. Dogwood is being treated like a speculative biotech name with enough upside torque that traders are still willing to pay ahead of clearer proof.

EWTX | Edgewise Therapeutics | $42.46. Edgewise is attracting buyers because its muscle-disease and cardiology programs give it a more defined clinical path than many small-cap peers.
BHB | Bar Harbor Bankshares | $38.04. Bar Harbor’s new high reflects a market still rewarding clean deposit franchises and stable regional-bank execution.
HNGE | Hinge Health | $72.39. Hinge Health is being priced as one of the few digital health names with enough scale and operating credibility to deserve a premium.

FULT | Fulton Financial | $23.96. Fulton’s strength fits the broader regional-bank bid, where investors are still favoring balance-sheet stability over faster-growth but riskier names.
IBB | iShares Biotechnology ETF | $183.04. IBB making a new high confirms that the biotech move is broad and institutional rather than just a single-name squeeze.
ASTH | Astrana Health | $42.57. Astrana is getting a better valuation because the market sees a healthcare-services model with more visible operating leverage than the average growth story.

BBC | Virtus LifeSci Biotech Clinical Trials ETF | $49.89. BBC is a biotech clinical-trials ETF, so this high says investors are still willing to reach further down the risk curve for early-stage biotech exposure.
MIRM | Mirum Pharmaceuticals | $115.87. Mirum is being rewarded for rare-disease execution, which is the kind of commercial story the market tends to pay up for when it is working.
AUPH | Aurinia Pharmaceuticals | $19.25. Aurinia is being treated more like an established autoimmune franchise now, which is why the stock keeps attracting a higher multiple.

CARE | Carter Bankshares | $33.05. Carter Bankshares is benefiting from the same regional-bank rotation that is rewarding smaller lenders with clean funding and credit profiles.
ABSI | Absci | $11.00. Absci is being valued more seriously as a platform story, with the market starting to give real weight to the company’s AI-enabled drug discovery angle.
GLW | Corning | $217.09. Corning’s move reflects investor confidence in a business mix that still looks like a durable compounder across materials and connectivity.

BAC | Bank of America | $58.33. Bank of America is benefiting from the market’s preference for scale, capital returns, and balance-sheet strength in financials.
MANE | Veradermics | $118.70. Veradermics is getting a higher bid because investors are starting to price the company around an active dermatology program rather than a blank clinical shell.
PBYI | Puma Biotechnology | $8.41. Puma is getting some support because the market still sees value in a commercial oncology name with survivability and optionality left in the story.

GENB | Generate Biomedicines | $16.79. Generate Biomedicines is being rewarded for its generative-biology platform, which keeps it squarely in the AI-driven drug design trade.
MBX | MoonLake Immunotherapeutics | $49.25. MoonLake remains one of the cleaner immunology growth names, and the market is still paying for that differentiated profile.
ROIV | Roivant Sciences | $32.80. Roivant is getting credit for the portfolio model, where investors can still underwrite multiple shots on goal instead of a single binary outcome.

BCAL | California Bank of Commerce | $20.78. BCAL is participating in the regional-bank trade because the market still prefers clean funding stories and disciplined credit management.
NECB | Northeast Community Bancorp | $27.04. Northeast Community Bancorp is staying in favor as investors continue to reward steady community-bank execution.
MGNX | MacroGenics | $5.08. MacroGenics is getting a lift because the market still sees enough oncology optionality to keep the name on the radar.

CFG | Citizens Financial Group | $69.95. Citizens is being re-rated with the larger regional-bank group as investors continue to favor names with scale and visible earnings power.
IBBQ | Invesco Nasdaq Biotechnology ETF | $31.51. IBBQ hitting a high confirms that the biotech bid is alive across multiple ETF wrappers, not just in the biggest benchmark funds.
PTGX | Protagonist Therapeutics | $124.80. Protagonist is still getting a premium because it has both a commercial asset and additional catalyst runway ahead, which is rare in biotech.

CLYM | Climb Bio | $12.81. Climb Bio is drawing more interest as a clinical-stage immune-disease company with a story the market is still willing to finance.
CGEM | Cullinan Therapeutics | $18.76. Cullinan is being supported because the market still sees enough oncology shots on goal to justify a higher valuation.
LFST | LifeStance Health Group | $9.86. LifeStance is being rewarded for proving that a behavioral-health platform can scale with better operating leverage.

RVMD | Revolution Medicines | $171.25. Revolution is one of the strongest oncology growth stories in the market, and the stock is behaving like a platform with serious long-term value.
EW | Edwards Lifesciences | $90.99. Edwards is being treated like a high-quality medtech compounder with a franchise investors trust to keep producing.
CYTK | Cytokinetics | $82.83. Cytokinetics is still drawing strong support because the market sees a real cardiovascular commercial opportunity ahead.

D | Dominion Energy | $69.42. Dominion is moving higher as the NextEra deal becomes more concrete, with the market increasingly pricing the stock on transaction terms and regulatory odds rather than standalone utility fundamentals news.dominionenergy+2.
52-Week Lows
INBS | Intelligent Bio Solutions | $2.18. Intelligent Bio Solutions is getting marked down because the market still wants commercial proof before assigning real value to the story.

CNTX | Context Therapeutics | $0.57. Context is being sold because the market is no longer paying much for distant optionality without a near-term catalyst.
VRXA | Vaxart | $2.80. Vaxart’s new low shows how little patience the market has for speculative vaccine stories that still need proof.
LENZ | LENZ Therapeutics | $5.56. LENZ is under pressure because investors remain cautious about how quickly it can turn its product story into durable value.

TVRD | Tvardi Therapeutics | $2.42. Tvardi is getting punished because the market still wants clearer evidence that the pipeline can translate into meaningful upside.
CVKD | Cadrenal Therapeutics | $2.55. Cadrenal remains under pressure as an early-stage story where proof is still ahead of valuation.
ATOS | Atossa Therapeutics | $1.75. Atossa is still being treated as a low-conviction biotech name where the market wants data rather than hope.

Summary
Yesterday was the Fed stress test day, and all 32 U.S. large-cap banks passed, which usually sets up the next leg of the trade: capital reallocation through dividend and buyback updates. That is the real backdrop behind the bank strength in names like BAC, CFG, BHB, FULT, and NECB, while the biotech tape stayed strong on its own catalyst-driven momentum. The key read-through is that the market is now shifting from balance-sheet fear to capital-return math, which tends to support financials after the test clears.

[M&A Hunter @TheBioMAHunter]

Wednesday DD Viridian Therapeutics (VRDN) Veligrotug and the Next Wave of IGF-1R Inhibition in Thyroid Eye Disease https://t.co/YeHulsTkeQ

[Biotech Distilled @BiotechHBI]

Biotech Distilled Top By Calls (https://t.co/zfTAlvBLuR)

[M&A Hunter @TheBioMAHunter]

@Pixie1z Fuk dudes

[M&A Hunter @TheBioMAHunter]

@MeadowCapital won't be for a year until P3 data reads out I have PFE buying it. M&A is kinda my thing!

[M&A Hunter @TheBioMAHunter]

@Merica815 @MeadowCapital 12m out

[M&A Hunter @TheBioMAHunter]

@Merica815 @MeadowCapital The main asset is in P3

[M&A Hunter @TheBioMAHunter]

@stocklllovers6 Shave your head & hand out flowers like a good cultist lol

[M&A Hunter @TheBioMAHunter]

Understanding Bank Dividend Raises & Buybacks (Why This Window Matters) https://t.co/qwZUO5ULrt

[M&A Hunter @TheBioMAHunter]

@Driller562 @stocklllovers6 I try telling them Dr. Pat has a playbook

[M&A Hunter @TheBioMAHunter]

@PK_Fund I do biotech M&A investing for a living & I have been tell the VKTX is getting sold folks not until the trial ends.

[M&A Hunter @TheBioMAHunter]

@YYDSxjm It's the face a scam artist with a long history of screwing retail investors.

[M&A Hunter @TheBioMAHunter]

@gainzalgo @grok What a scammer Dr. Pat is always has been & look into his last 2 M&A exits. He drove the shares down shaking out retail including Cher the singer then after the shakeout heavy insider buying raises the price then M&A happens & the insiders get rich & retail loses out

[M&A Hunter @TheBioMAHunter]

@PSchiermeyer32 @SparksN123

[Jason Cohen 🇺🇸 @JasonJournoDC]

💥NEW: Stephen A. Smith: "EVERY time we turn around, there's something going on in Chicago! Every time! And the vast majority of victims happen to be black."

"When we gon' speak about that? Same energy, y'all. Don't lose the intensity. Keep the same intensity."

"We gon' fight and fight and fight over a young kid [Karmelo Anthony] that admitted he killed somebody — and we hear CRICKETS when 39 people get shot and 6 get killed in Chicago on JUNETEENTH!?"

[M&A Hunter @TheBioMAHunter]

@PJamess69 I do biotech M&A investing for a living VKTX won't sell until after the P3 ends

[M&A Hunter @TheBioMAHunter]

The IBRX Dr. Pat Cult is wild. This guy is a scam artist who ripped off retail investor MANY times. If you don't believe me look it up.

Cher Lawsuit (Altor BioScience, 2017)
Details: Cher sued Soon-Shiong, Altor Acquisition LLC, and others in Los Angeles Superior Court (Case No. BC677768). She alleged fraudulent concealment and breach of fiduciary duty.

Cher also filed a follow-up action accusing Soon-Shiong’s associates of lying about her during the defense.

Lawsuits from His Brother, Terrence Soon-Shiong (1990s)

Sorrento Therapeutics “Catch and Kill” Lawsuits (2019)

Investor/Securities Suits: Multiple class actions and individual suits against NantHealth and NantKwest (pre-IBRX entities) alleging misstatements or failures to disclose information to investors.

Minority Shareholder Suits (Altor and others): Similar claims around acquisitions and valuations.

Recent (2024): Dispute involving a nonprofit medical research group (AAHI) where Soon-Shiong (as a board member and funder via his foundation) faced allegations of fiduciary duty violations over funding decisions. He described it as an attempted “coup.”

[M&A Hunter @TheBioMAHunter]

@alc2022 Wow the cult of Dr. Pat is wild. Dr. Pat is a scam artist who has screwed over retail many times over look into his past even CHER sued him once

[M&A Hunter @TheBioMAHunter]

@avidresearch Amgen’s MariTide is the closest out there but not the side effect profile you asked about they are around 20-22%

[M&A Hunter @TheBioMAHunter]

@bioinvestor24 Very true at least until GPCR comes to market GPCR has the best GPL hands down